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Abstract 
Objective: To evaluate the effect of GONB, with or without trigger point injection (TPI), 
on dynamical mechanical (brush) allodynia (BA) and on head pain in migraine.  
Background: Patients with migraine often have cutaneous allodynia, which is related to 
sensitization of central pain neurons. Greater occipital nerve block (GONB) is an 
effective treatment for migraine headache, however its effect on cutaneous allodynia in 
migraine is unknown. 
 Methods: We studied patients with migraine and BA who were treated with GONB with 
or without TPI. Demographic data, migraine history and headache features were 
documented. Allodynia was evaluated using a structured questionnaire and by applying 
a 4x4-inch gauze pad to skin areas in the trigeminal and cervical dermatomes. Degree of 
allodynia (the allodynia score) was measured on a 100 mm visual analog scale (VAS) 
before treatment and 10 and 20 minutes thereafter. Headache levels were assessed using 
an 11-point verbal scale. Allodynia scores, as well as headache levels, before and after 
treatment were compared.  
Results: Nineteen patients were studied. Mean age was 43.6± 11.8 years. Twenty 
minutes after treatment, headache was reduced in 17 patients (89.5%) and did not change 
in two (10.5%). The average headache level was 6.53 before treatment and 3.47 twenty 
minutes after it. The average allodynia score decreased after 20 minutes in all patients. 
Average allodynia score per site was reduced by 18.69 mm and 13.74 mm in the 
trigeminal and cervical areas, respectively. There was a positive correlation between 
allodynia index, obtained through the questionnaire, and allodynia score, obtained by 
examination.   
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Conclusion: GONB, with or without TPI, reduced both head pain and brush allodynia in 
this migraine patient group.  
 
Key words: greater occipital nerve block; migraine; allodynia 
 
Abbreviations:  
GONB - greater occipital nerve block 
TPI - trigger point injection 
BA - brush allodynia 
EM - episodic migraine  
TM - transformed migraine 
VAS - visual analog scale 
NSAIDs – non steroidal anti-inflammatory drugs 
DNIC - diffuse noxious inhibitory control  
TNC - trigeminal nucleus caudalis  
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Introduction 
Patients with migraine often have increased skin sensitivity to non-noxious stimuli 
(cutaneous allodynia).1,2 This phenomenon is related to sensitization of central pain 
neurons receiving convergent input from both intracranial structures and skin.3,4 Greater 
occipital nerve block (GONB) is an effective treatment for migraine pain in a significant 
proportion of patients.5 It may alleviate head pain by altering the nociceptive input to the 
trigemino-cervical complex. Its effect on cutaneous allodynia in migraine, however, is 
currently unknown. 
The aim of this study was to evaluate the effect of GONB, with or without trigger point 
injection (TPI), on dynamical mechanical (brush) allodynia (BA) and on head pain in 
patients with migraine.  
 
Patients and Methods 
This study was approved by the Institutional Review Board of Jefferson University 
Hospital. We studied adult (age >18 years) patients with IHS-defined episodic migraine 
(EM) or transformed migraine (TM) as defined by Silberstein and Lipton 6. All patients 
had BA and were treated with GONB with or without trigger point injection (TPI). 
GONB was performed by injecting 2 cc of 2% lidocaine and 5 mg triamcinolone, 2 cm 
lateral to the occipital protuberance. For TPI, 0.5 cc of 2% lidocaine was injected 
intramuscularly. Demographic data, migraine history and characteristics of the pain were 
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documented. A migraine score was calculated by multiplying the attack frequency (per 
month) by attack duration (in hours).  
An allodynia questionnaire was given to the patients. It consisted of questions about head 
pain evoked or made worse by various non-noxious stimuli: tilting or bending down the 
head, coughing, climbing stairs, touching the scalp or face, shaving (for men) or wearing 
jewelry (for women), wearing tight collars and exposure to wind. An allodynia index was 
determined by adding the number of positive answers to the above seven questions, with 
a result ranging from 0 to 7. Allodynia was also evaluated by repetitively applying a 4x4-
inch gauze pad to various skin areas in the trigeminal (V1, V2, V3) and cervical (C2, C5, 
C8) dermatomes. The gauze was applied ten times at a rate of 2/sec. Degree of allodynia 
(the allodynia score) was measured on a 100 mm visual analog scale (VAS) before 
treatment and 10 and 20 minutes thereafter. Allodynia scores, as well as pain levels, 
before and after treatment were compared. The allodynia scores, obtained by 
examination, were also compared to the allodynia index as obtained per history.  
 
Results 
Nineteen patients (15 females and four males) were studied. Mean age was 43.6± 11.8 
years. Eighteen patients had transformed migraine (TM) and one had episodic migraine 
(EM). Four underwent GONB alone and 15 had GONB with TPI. Seven patients had an 
acute IHS-defined migraine attack when treated, with an average time of 29.2±11.3 hours 
between the beginning of the attack and the GONB treatment. Six patients had taken an 
acute migraine drug during the 24 hour period prior to GONB treatment. The shortest 
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interval between acute medication treatment and GONB was 3 hours.  Seventeen patients 
were on migraine-preventive drugs [12 on antidepressants (nortriptyline, amitriptyline, 
desipramine, venlafaxine, fluoxetine, sertraline), 12 on anticonvulsants (topiramate, 
valproic acid, oxcarbazepine, gabapentin, levetiracetam), 5 on calcium channel 
antagonists (verapamil, amlodipine), 3 on NSAIDs (naproxen, celecoxib, rofecoxib), 3 on 
muscle relaxants (tizanidine, metaxalone) and 3 on antipsychotics (chlorpromazine, 
quetiapine, ziprasidone)] with an average of 2.82 drugs per patient.  
Twenty minutes after treatment, pain was reduced in 17 patients (89.5%) and did not 
change in two (10.5%).  The average pain score before treatment was 6.53 (on a scale of 
0-10) and it decreased to 3.47 twenty minutes after treatment (P<0.001) (Figure 1). In the 
cervical dermatomes, the average allodynia score was significantly higher at C2 (28.39) 
compared to both C5 (19.00, p=0.014) and C8 (16.13, p=0.002) prior to treatment (Figure 
2). The average allodynia scores decreased after 20 minutes for all patients. Average 
allodynia score per site in the trigeminal areas was reduced by 18.69 mm (from 28.42 
before treatment to 9.73 after it) and in the cervical areas it was reduced by 13.74 mm 
(from 20.08 to 6.34) (p<0.001) (Figure 3). Average allodynia was (non-significantly) 
more severe on the left (26.0) compared with the right (22.5) prior to treatment 
(p=0.594). Head pain reduction was (non-significantly) smaller on the left (2.50 [from 
7.25 to 4.75]) compared with the right (3.87 [from 6.50 to 2.63]) (p=0.099).  
Data analysis on the side of GONB in relation to the side of allodynia reduction showed 
that GONB reduced allodynia scores by 65.7% ipsilaterally and by 59.2% contralaterally.  
The average allodynia index (per history) for the entire group was 4.16 (on a scale of 0-
7). There was a significant positive correlation of between the average allodynia score 
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and the allodynia index (p=0.014) (Figure 4). A positive correlation between the 
allodynia score and the migraine score did exist, however, that correlation did not reach 
statistical significance (p=0.304). 
 
Comments 
GONB, with or without TPI, reduced both head pain and allodynia in this study. The high 
proportion of patients responding to GONB in our study (89.5%) is similar to that found 
in previous reports.5 The effect of GONB on allodynia in our study was similarly high 
(100%).   
Our results suggest an effect of GONB on sensitized neurons in the trigemino-cervical 
complex, resulting in a reduction of both head pain and cutaneous allodynia. The 
mechanism of action of GONB is incompletely understood. It may be related to the 
anesthetic effects of the drugs injected, or to the physical effect of the injection itself on 
the nerve via a diffuse noxious inhibitory control (DNIC) mechanism.7,8 Since we did not 
compare the effect of GONB with anesthetic drugs to that of sham injection of the nerve, 
we can not conclude as to the exact mechanism of action of GONB, nor could we assess 
the extent of a placebo effect of the procedure.  
The results of allodynia testing in our study may have been affected by the preventive 
medications that the majority of patients were on. However, the exact effect of preventive 
medications on the occurrence of cutaneous allodynia in migraine is currently unknown.   
Other limitations of the study are the heterogeneity of the study population and the fact 
that some patients had TPI in addition to the GONB. In addition, some patients were 
overusing acute pain medications, which may have affected their response to GONB.  
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The effect of GONB on allodynia in the different dermatomes was not uniform. It was 
significantly higher in the trigeminal area compared with the cervical dermatomes. This 
suggests, but does not prove, a contiguous spread of GONB effect on sensitized neurons 
in the trigemino-cervical complex, with neurons in the trigeminal nucleus caudalis (TNC) 
affected first and to a higher degree than those in the cervical segment of the spinal cord. 
An alternative explanation is that neuronal sensitization in migraine is a process 
involving first-, second- and third order neurons sequentially as suggested by Burstein et 
al.1,2 These hypotheses need to be further assessed by electrophysiologic studies, such as 
single cell recordings from neurons in the TNC, cervical spinal cord and thalamus in 
animal models. It should be noted that the results of allodynia reduction in the cervical 
dermatomes need to be interpreted with caution since some patients were given TPI in the 
same or adjacent areas to the ones tested for allodynia.  
In this study we show a significant reduction of allodynia by GONB not only ipsilaterally 
but also, and to a similar extent, contralateral to the block. This suggests a spread of the 
GONB effect across the midline, through a multi-synaptic pathway. The anatomy of this 
putative pathway, however, is currently unknown.  
The severity of allodynia may correlate with migraine attack frequency and duration 
(which is presented in our study as the migraine score) although this correlation did not 
reach statistical significance. This suggests that allodynia may be a manifestation of long-
standing neuronal hyper-excitability which in turn results from repeated frequent 
migraine attacks. This notion is supported by recent findings of a correlation between the 
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duration of disease and the occurrence of cutaneous allodynia in cluster headache patients 
9.
Analysis of our data separately for head pain in each side showed that pain reduction 
after GONB was less pronounced on the side where allodynia was more severe (left). 
This is in accordance with previous reports showing that the development of cutaneous 
allodynia in migraine is a predictor of poor response to treatment of a migraine attack 
with triptans 10. Finally, we found our allodynia questionnaire to be valid and to correlate 
well with the scores of allodynia per examination.  
In summary, in this study we show that GON block, with or without TPI, reduces both 
pain and allodynia in migraine patients. This pilot study should be followed by a larger 
controlled trial to further assess the effects of GON block and TPI on headache and 
allodynia in migraine, and to differentiate between the effects of the two procedures on 
these parameters.  
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Legends: 
 
Figure 1:  Average pain reduction after treatment with GONB ± TPI 
Figure 2:  Average allodynia scores per site before treatment in the different areas 
Figure 3: Average allodynia scores per site before and after treatment 
Figure 4: Correlation between the allodynia index (obtained by a questionnaire) and 
allodynia scores (obtained by examination) 
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Fig. 1 
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Fig. 2 
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Fig. 3 
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Fig.4 
 
Plot of Average Allodynia Score vs Allodynia Index
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